Menu Search
Equities

Implanet SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
IM11:FRA

Implanet SA

Actions
  • Price (EUR)0.225
  • Today's Change-0.003 / -1.32%
  • Shares traded17.35k
  • 1 Year change+130.08%
  • Beta0.2063
Data delayed at least 15 minutes, as of Feb 06 2026 07:36 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Implanet SA is a France-based medical technology company. It is involved in the design, production and marketing of medical equipment, such as medical implants and devices used in orthopedic surgery. The Company's products include prosthetic knees, spinal bracing systems, intersomatic cages, pins, suture threads, screws, and anchors, among others. Its activities, and flagship products, include JAZZ (Spine System) and MADISON (Knee implant). JAZZ implant is designed to improve the treatment of spinal pathologies requiring vertebral fusion surgery. MADISON implant is designed for first-line prosthetic knee surgery.

  • Revenue in EUR (TTM)11.10m
  • Net income in EUR-4.81m
  • Incorporated2006
  • Employees44.00
  • Location
    Implanet SATechnopole Bordeaux MontesquieuAllee Francois MagendieMARTILLAC 33650FranceFRA
  • Phone+33 557995555
  • Fax+33 557995700
  • Websitehttps://www.implanet.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.